Secrin 2mg Tablet

Secrin tablet is indicated in following conditions-

• Secrin is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
• Secrin may be used concomitantly with metformin when diet, exercise, and Secrin or metformin alone does not result in adequate glycaemic control.
• Secrin is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent.
• Combined use of Secrin and insulin may increase the potential for hypoglycaemia.

Pharmacology

Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion.

Administration

Glimepiride tablet must be swallowed with sufficient amount of liquid.

Interaction

Based on experience with Secrin and known interactions for other sulfonylureas, the following interactions must be considered.

Contraindications

Glimepiride is not suitable for the treatment of insulin dependent (type I) diabetes mellitus, or for the treatment of diabetic ketoacidosis, nor for the treatment of diabetic coma. Glimepiride must not be used in patients hypersensitive to Glimepiride, other sulfonylureas, other sulfonamides, severe hepatic dysfunction, severe impairment of renal function and dialysis patients.

Side Effects

Hypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, fall in blood pressure.

Pregnancy & Lactation

Glimepiride must not be taken during pregnancy; a changeover to insulin is necessary. Patients planning a pregnancy must inform their physician, and should change over to insulin. Ingestion of Glimepiride with breast milk feeding may harm the child. Therefore, Glimepiride must not be taken by breastfeeding women. Either a changeover or complete discontinuation of breastfeeding is necessary.

Precautions & Warningsin

the initial weeks of treatment, the risk of hypoglycaemia may be increased and necessitates careful monitoring. If such risk present it may be necessary to adjust the dosage of Secrin, Hypoglycaemia can almost be promptly controlled by immediate intake of carbohydrates (glucose or sugar).

Overdose Effects

Overdosage of sulfonylureas, including Secrin, can produce hypoglycaemia. Mild hypoglycaemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. 

Therapeutic Class

Sulfonylureas

Storage Conditions

Do not store above 30°C. Keep away from light and out of the reach of  children